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A B S T R A C T
The objective of the present investigation was to formulate nanoparticles constructed using
PLGA polymer for the effective targeted delivery to brain via nasal route. The PLGA
nanoparticles were optimized using novel design of experiment technique by 23 full facto-
rial design. Drug: polymer ratio (X1), surfactant concentration (X2) and stirring speed (X3) were
identified as critical process parameters, and its impact on particle size (Y1) and % entrap-
ment efficiency (Y2) was studied. The optimized nanoparticle formulation was conjugated
with glutathione as an endogenous ligand by using carbodiimide chemistry using (1-Ethyl-
3-(3-dimethylaminopropyl)carbodiimide) (EDAC) as linker molecule. From Ellman’s assay,
it was found that a total of 691.27 ± 151 units of glutathione were conjugated upon each
PLGA nanoparticle. The in vitro release studies as well as ex vivo studies revealed biphasic
pattern of drug release with initial burst release followed by slow exponential release of
drug over a period of 24 h. The in vivo biodistribution studies were conducted on rat fol-
lowing nasal administration of the nanoparticle formulation (conjugated and unconjugated)
and were compared with plain paclitaxel suspension.The results clearly demonstrated that
the brain targeting efficiency was enhanced with the glutathione conjugated formulation
(387.474%) as compared to the unconjugated nanoparticle formulation (224.327%). Further,
the in vitro in vivo correlation studies revealed good relationship (R2 > 0.95) as obtained from
the levy plot. Glutathione proves to be an efficient vector for the successful transport of poor
bioavailable drug to the brain.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-






In vitro in vivo correlation (IVIVC)
1. Introduction
Nanoparticulate delivery systems [1], such as those based on
poly (lactic-co-glycolic acid) (PLGA) have been studied exten-
sively for many years. For the past three decades, lot of
researchers has explored PLGA to fabricate drug delivery
systems for pharmaceutical and biomedical applications
due to its biocompatible and biodegradable properties. PLGA,
further, has the advantage of being well characterized and
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commercially used for microparticulate and nanoparticulate
drug delivery systems [2]. PLGA polymer is one of the most
common biodegradable polymers used for the controlled de-
livery of drugs due to its early use and approval as a compatible
biomaterial in humans. Lewis (1990) reported that, by varying
the molecular weight and lactide/glycolide ratio, the degrada-
tion time of the PLA and PLGA and the release kinetics of the
active agent can be controlled [3]. In aqueous media, degra-
dation of PLGA is triggered by hydrolysis of its ester linkages.
Presence of methyl side groups in PLA makes it more hydro-
phobic than PGA, and hence lactide rich PLGA copolymers are
less hydrophilic, absorb less water and degrade more slowly
and control the release of drug for prolonged duration [4,5].
The major advantages of nanoparticles is improved
bioavailability by enhancing aqueous solubility, increasing re-
sistance time in the body (increasing half-life for clearance/
increasing specificity for its associated receptors and targeting
drug to specific location in the body.This is why nanoparticles
are increasingly used in variety of applications that includes
drug carrier systems and to pass organ barriers such as the
blood–brain barrier, cell membrane, etc. The cellular uptake,
biodistribution and circulating half-life are the key factors which
are influenced by particle size of nanoparticles.Therefore, par-
ticle size becomes a primary concern while formulating a
nanoparticulate system [6]. Moreover the particle size thus ob-
tained should be uniform becausemore uniform the distribution
of particles more consistent will be the biodistribution, cellu-
lar uptake and drug release [7].
Nasal route is one of the alternative approaches for deliv-
ery of drugs to brain, where the drug is absorbed into the
systemic circulation through nasal mucosa.Anatomically, nasal
mucosa is comprised of tight junctions, and molecules with
smaller size (less than 10 nm) can be able to traverse the junc-
tions to reach the systemic circulation. Normally, many
hydrophobic drugs or formulations (200 nm or more) opt
transcellular route for delivery across the nasal mucosa.
Nanoparticles above 500 nm size fall prey to the mucociliary
clearance or by triggering immune response. The lower the
particle size of nanoparticles, the more will be the rate
of permeation across the nasal mucosa via transcellular
pathway [8,9].
Paclitaxel (PTX) is one of the most widely used chemo-
therapeutic agents against breast and lung cancer, however,
the brain delivery of paclitaxel is restricted owing to several
bodily defense mechanisms. However, P-glycoprotein, an ATP-
binding cassette (ABC) transporter, acts as a barrier in cancer
treatment by chemotherapy by multidrug resistance (MDR) at
cellular/non-cellular level offered by the tumor cells [10].There-
fore, the absorption of paclitaxel is minimized due to rapid
efflux of the drug out of the tumor cell because of the
overexpression of the plasma membrane, P-glycoprotein (P-
gp) [11,12]. Hence, nanoparticles consisting of Poly(Lactide-co-
Glycolide (PLGA) have proven to possess potential delivery of
insoluble drugs like paclitaxel to target areas, as they can be
endocytosed/phagocytosed by cell resulting in the internal-
ization of the encapsulated drug in the cell. PLGA, due to its
biodegradability and biocompatibility, has attracted consider-
able attention for developing polymeric nanoparticles. PLGA
possesses many advantages, such as able to encapsulate hy-
drophilic and hydrophobic drugs, improves interaction with
biological matters and imparting stealthness, enhancing sta-
bility of drug, etc. [13,14].
Glutathione (GSH) is a hydrophilic endogenous tripeptide
molecule that performs antioxidant function against reactive
species and toxic metabolites of the cell [15]. Glutathione helps
in transporting few endogenous substances across the blood–
brain barrier (BBB) by interacting with the membrane proteins
in the BBB [16]. Normally, P-glycoprotein (P-gp), the gate-
keeper of BBB, helps in transporting the glutathione coupled
compounds across the BBB [17]. This mechanism is exploited
for the delivery of paclitaxel to the brain by coupling it with
glutathione.
Paclitaxel, belonging to BCS class IV, exhibits limited
absorption due to its poor solubility and permeability charac-
teristics. Paclitaxel, due to its poor permeability to brain, is
primarily indicated for breast cancer and small cell lung cancer.
Hence, paclitaxel is a suitable candidate for formulating
nanoparticles due to its safe and efficient targeting of drug to
the brain. In view of pursuing the objective of fostering the de-
velopment of size controlled nanoparticles with enhanced
entrapment efficiency, novel quality by design concept was uti-
lized. Further, the optimized nanoparticles were conjugated with
glutathione and assessed the functionalization of nanoparticles
with respect to its ability to transport drug across BBB.
The objective of the present investigation emphasizes the
preparation of nanoparticles by using novel design of experi-
ment concepts and subsequently conjugating with glutathione
on the surface of nanoparticles. Hence, an attempt is being
made in the current research to enhance the brain delivery of
paclitaxel by loading PLGA nanoparticles conjugated with glu-
tathione, which was further assessed by in vivo biodistribution
studies.
2. Materials and methods
2.1. Materials
PLGA copolymer RG 502-H (lactide : glycolide ratio of 50:50,mo-
lecular weight 7–17 kDa), Resomer RG 504-H (lactide : glycolide
ratio of 50:50, molecular weight 38-54 kDa) was obtained as gift
sample from Evonik Industries AG, Germany. Poloxamer 188
was supplied as a gratis sample from Sandoz Pvt. Ltd, Mumbai.
DCM (purity NLT 99% by GC), Paclitaxel was obtained as gratis
sample from MAC-CHEM products Pvt. Ltd, Mumbai. Glutathi-
one was purchased from SD Fine Chemicals, Mumbai. Dialysis
membrane – Himedia LA401-5MT, Acetone (purity NLT 99% by
GC),methanol (HPLC grade) were procured fromMerck and Co.,
Germany. Double distilled water used was filtered through
0.22 μm filter from Millipore (Mumbai, India). All other cited
chemicals used were of analytical grade.
2.2. Animals
Adult maleWistar rats weighing 200–240 g acquired from dedi-
cated animal house of Institute of Pharmacy, Nirma University
after receiving approval from the Institutional Animal
Ethics Committee (IAEC) dated 15/06/2013 for studying the
biodistribution potential of the formulation (Protocol No. IP/
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pcog/phd/13-1/021). All the experiments were performed as per
the guidelines laid down by CDSCEA, India.
2.3. Preparation of paclitaxel loaded PLGA nanoparticles
The nanoparticles were developed by employing nanopre-
cipitation technique [18] using PLGA poly (lactic-co-glycolic acid)
copolymer. Briefly, an organic solution containing specified
amount of PLGA polymer and Paclitaxel was added to an
aqueous solution containing a suitable surfactant in a drop wise
manner under vigorous stirring followed by magnetic stir-
ring at room temperature. Later, the dispersion was kept for
magnetic stirring (200 ± 50 RPM) for 6 h at room temperature
to evaporate the organic solvent.The precipitated nanoparticles
were separated by ultracentrifugation and dried using vacuum
drying to obtain free flowing dried nanoparticles [19] and stored
at 4 °C for further studies.
In the present investigation, for establishment of design
space, a 23 full factorial design was employed to assess the in-
fluence of three factors, i.e., Drug: polymer ratio (X1), a
concentration of Poloxamer 188 (X2) and stirring speed (X3) on
particle size (Y1) and percentage entrapment efficiency (Y2) of
nanoparticles.The response(s) obtained are measured for each
experiment and analyzed by either linear or multiple regres-
sion models. However, the change in one independent variable
and its influence on the responses can be studied by employ-
ing response surface methodology (RSM).The RSM and contour
plots can be obtained by employing the regression equation,
and the impact of each variable on the response variables can
be studied effectively. Regression analysis was performed to
develop a polynomial model for the estimation of the average
particle size and % entrapment efficiency.
Y X X X X X X= + + + + + ……β β β β β β0 1 1 2 2 3 3 12 1 2 11 3 (1)
Where Y represents the response, while,X1, X2 and X3 denote
the main effects of factors. Equation 1 above signifies simple
regression equation for obtaining response surface and contour
plots where β0 is a constant and β1, β2, β3 are the coefficients
of the factors.The P-values of the regression coefficients as well
as ANOVA were determined in order to evaluate the signifi-
cance of the variables on the CQAs and significance of the
model, respectively.
The design space may be obtained from overlay plots after
plotting contour plots and response surface plots based on the
desired range of values for the CQAs after which the formu-
lation and process were optimized with respect to particle size
and % entrapment efficiency. Several trials were conducted to
ascertain the correlation between the predicted and the prac-
tical values in order to validate the optimized process or
formulation [20].
2.4. Conjugation of PLGA nanoparticles with glutathione
The paclitaxel loaded PLGA nanoparticles were conjugated with
glutathione on their surface by utilizing the carbodiimide chem-
istry.This involves two steps, first step comprises the activation
of carboxyl groups on the surface of the nanoparticles by EDAC
(1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide) followed by
the nucleophilic addition of glutathione on to the activated
functional groups of nanoparticles. The carboxyl group acti-
vation process involves incubation of prepared nanoparticles
(100 mg) with 4 ml of EDAC solution (50 mg/ml) for 45 min at
room temperature. Later, the free unreacted EDAC was sepa-
rated by centrifugation for 15–20 min at 3500 rpm and re-
suspended the activated nanoparticles in 4 ml of buffer solution
containing glutathione (50 mg/ml) under gentle stirring (200–
250 rpm) for 6 h. The un-conjugated glutathione was then
separated by centrifugation at 3500 rpm for 15–20 min and
vacuum dried to obtain free flowing glutathione conjugated
nanoparticles [21–23]. The prepared formulation was trans-
ferred to clean vials and stored for further evaluation studies.
2.5. Entrapment efficiency, particle size and size
distribution analysis
Quantitative determination of Paclitaxel in nanoparticles was
performed using HPLC (JASCO with PDA detector and manual
injector with 20μl loop). Briefly, 30 mg of nanoparticles formu-
lation was taken in 10 ml of methanol, and the drug entrapped
in the nanoparticles was extracted at room temperature by
using sonication technique for 3 h. After 3 h, the undissolved
matter was separated by filtration through 0.2 μ polyte-
trafluoroethylene membrane filters, and the amount of drug
was analyzed by HPLC. Entrapment efficiency (EE) of the
nanoparticles was calculated from equation 2:
% Entrapment efficiency





The average particle size and size distribution of Paclitaxel
loaded PLGA nanoparticles was determined using particle size
analyzer which works on the principle of dynamic light scat-
tering technique (Nanophox, Sympatec GmbH, System-Partikel-
Technik, Clausthal-Zellerfeld, Germany). The measurements
recorded indicate average volumemean diameter 30 of samples
conducted in triplicate. 5g of the prototype nanoparticulate for-
mulation was diluted in 100 ml of double distilled water and
sonicated for about 3–5 min to declump the aggregates, and
the resulted dispersion was analyzed for particle size at 250C.
The width of the particle size distribution is articulated by
means of span value (equation 3) which can be calculated by










2.6. Zeta potential analysis
Zeta potential refers to the charge on the surface of the
nanoparticles which in turn plays a pivotal role in the stabil-
ity of colloidal dispersions.The zeta potential value designates
the extent of repulsive forces between the particles in disper-
sion which aids in preventing the agglomeration of particles
upon storage. Lower zeta potential value leads to flocculated
dispersion as the attractive forces dominate the repulsive forces
and the particles unite to form aggregates. Zeta potential of
the Paclitaxel loaded PLGA nanoparticles was analyzed using
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Zetasizer Nano (Malvern instruments, UK) by dispersing the
sample in double distilled water followed by gentle sonica-
tion for disaggregation of particles.
2.7. Quantification of glutathione in conjugated PLGA
nanoparticles by Ellman’s assay
Ellman’s reagent (5,5’-dithiobis-(2-nitrobenzoic acid) or DTNB)
is used to quantitatively determine the number of glutathi-
one units conjugated on the surface of each nanoparticle
surface. Ellman’s reagent was added to 5ml of phosphate buffer
pH 7.2 containing 60 mg of conjugated and un-conjugated
nanoparticles and 1 mM EDTA and kept for 15–20 min at room
temperature. The supernatant was collected by centrifuga-
tion for 15–20 min at 3500 rpm, and the thiol content was
estimated by HPLC after addition of 2 ml of sodium hydrogen
phosphate (0.2 M) against unconjugated nanoparticles as blank.
The number of glutathione units conjugated on the surface of
the PLGA nanoparticles was calculated by using the formula
(equation 4) [26,27]:






Where, n = thiol functionality of glutathione unit per
nanoparticle; a = mole of thiol per gram of PLGA; d = density
of nanoparticles; r = mean radius of nanoparticles and
N = 6.011 × 1023 (Avogadro number). Density of PLGA
nanoparticles was determined by mercury porosimetry analy-
sis, and the size, shape and diameter of the nanoparticles was
obtained from laser light scattering studies.
2.8. In vitro release study
The in vitro release of Paclitaxel from optimized PLGA
nanoparticles was performed using dialysis bag technique. Di-
alysis bag (Himedia,molecular weight cut-off 12000 Da,Mumbai,
India) was activated by soaking in the release medium over-
night. Phosphate buffer pH 6.0 + 0.5% SLS, pH 4.0 + 0.5% SLS and
pH 7.4 + 0.5% SLS were used as diffusion media which mimics
the nasal mucosal microenvironment pH, brain microenviron-
ment pH as well as physiological pH, respectively. The brain
targeted polymeric nanoparticles, administered via intra-
nasal route, enter the systemic circulation from the nasal
mucosa and later reach the brain. Hence, the release behav-
ior of the nanoparticles is studied at the respective pH.
Nanoparticles equivalent to 5 mg of Paclitaxel were placed in
the dialysis bag and immersed in the release medium after
sealing both the ends with clips and kept at 370C under con-
tinuous stirring at 75 rpm. 2 ml aliquots were withdrawn from
the medium at predetermined intervals of time, filtered with
0.45 μ polytetrafluoroethylene membrane filters and assayed
for drug content by HPLC [28,29]. Same amount of diffusion
medium was replenished in order to maintain the sink con-
dition to promote diffusion of drug into surrounding medium.
2.9. Ex vivo permeation study
The permeability potential of PLGA nanoparticles conjugated
with glutathione was assessed by ex vivo studies on sheep nasal
mucosa which was procured from animal slaughter house. In
order to correlate the in vitro release behavior of Paclitaxel from
PLGA nanoparticles, ex vivo studies were performed using Franz
diffusion cell.The receptor compartment was filled with phos-
phate buffer pH 6.0 + 0.5% SLS, and the nasal mucosa was
mounted on the receptor compartment on which the opti-
mized formulation was placed, and the study was performed
at 37 °C, 50–100 RPM. Phosphate buffer pH 6.0 was selected for
the study as it mimics the nasal environment pH. Periodi-
cally at predetermined intervals of time, 2 ml of sample was
withdrawn from the receptor compartment and subsequently
replenished with fresh buffer solution to maintain sink con-
dition. Further, the samples were diluted appropriately and
analyzed by HPLC against blank nanoparticles. The amount of
Paclitaxel released from the formulation at different time points
was calculated [30,31]. Further, the release model kinetics was
determined by using DD solver add in program.
2.10. In vivo biodistribution study
The targeting efficiency of glutathione conjugated PLGA
nanoparticles following nasal administration was investi-
gated in rats. A total of 18 healthy adult Wistar rats each
weighing around 200–350 g was used for the study.The animal
studies were conducted as per the protocol and guidelines ap-
proved and laid down by the Institutional Animal Ethics
Committee (IAEC) and Committee for the Purpose of Control
and Supervision of Experiments on Animals (CPSCEA) guid-
ance. Animals were kept in large spacious cages to provide
enough movement of animal and were sufficiently fed with
food and water and maintained on 12:12 h light/dark cycle.The
rats were divided into three groups representing six animals
in each group. First group was kept as control and received plain
Paclitaxel solution. Group II received Paclitaxel loaded PLGA
nanoparticles, whereas the Group III with glutathione conju-
gated Paclitaxel loaded PLGA nanoparticles. In the experimental
context, the formulations were administered intranasally at
a dose of 2 mg/kg body weight of Paclitaxel. During nasal ad-
ministration, the animal was held in the back in slant posture,
and the formulation was administered in each nostril swiftly
using micropipette attached with LDPE tubing, having 0.1 mm
internal diameter at the delivery site, thus allowing the
animal for proper breathing [32]. At specified intervals, the
biodistribution study was evaluated by checking the uptake of
Paclitaxel by different organs like brain, liver, spleen, lungs and
kidneys. Hence, the animal was sacrificed and the organs are
separated and washed completely with phosphate buffer saline
pH 7.4 in order to isolate all the adsorbed fluorescein and is
stored at −20 °C for further studies.The organs separated were
then homogenized in phosphate buffer saline pH 7.4 for fluo-
rescein extraction from the organs. Later, the suspension was
centrifuged, and the supernatant obtained was quantified by
HPLC to analyze the total amount of fluorescein distributed in
the organs [33,34].
The pharmacokinetics of the developed nanoparticle for-
mulation was compared with plain paclitaxel suspension for
assessment of its biodistribution potential. The ability of the
formulation to cross the blood–brain barrier and reaching the
brain is assessed by calculating the brain targeting efficiency
of the respective formulation.The brain targeting efficiency (BTE)
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of paclitaxel loaded nanoparticulate formulations was as-
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In vitro in vivo correlation (IVIVC) is used to establish a re-
lationship between in vitro dissolution and in vivo data. IVIVC,
according to FDA, is a predictive model describing relation
between in vitro property and in vivo response [36]. IVIVC was
obtained by plotting percentage of drug absorbed in vivo against
percentage of drug dissolved in vitro. This plot is called Levy
plot, and the percentage of drug absorbed (% Fa) is obtained
by Wagner-Nelson method by using equation 6 [37]:
% F C K AUC K AUCa t e e= +( ) ×− −∞0 0 100t (6)
Where, Fa = percentage of drug absorbed, Ct = concentra-
tion of drug in plasma at time t, Ke = elimination rate constant,
AUC 0-t and AUC 0-∞ = area under curve from the drug plasma
concentration – time curve from 0–48 h and 0-∞, respectively.
While performing IVIVC analysis, linear regression analy-
sis was also implemented in order to relate the in vivo drug
absorption to release of drug in vitro. The data are reported in
the form of mean ± standard deviation, and statistical analy-
sis was conducted using t-test. The data with P < 0.05 was
regarded as statistically significant.
2.11. Statistical analysis
All the experiments were performed in triplicate, and the results
obtained are presented as mean ± SD of the population. One
way analysis of variance (ANOVA) and regression analysis was
performed to evaluate the statistical significance of the dif-
ferences by considering P < 0.05 for demonstrating statistically
significant procedure. All the statistical evaluations were con-
ducted using Minitab®16 statistical software (USA).
3. Results and discussion
3.1. Particle size, distribution and zeta potential
Particle size is an important factor in the biodistribution of the
formulation among different organs in the body. The particle
size of paclitaxel loaded PLGA nanoparticles was found to be
in the range of 92.6 nm to 1080 nm, and several parameters
were found to affect particle size. The screening studies of in-
dependent variables established the influence of various factors
on particle size and entrapment efficiency of paclitaxel loaded
PLGA nanoparticles. Acetone was selected as anti-solvent as
it produced nanoparticle with average particle size of
159.7 ± 4.6 nm, whereas ethanol and dichloromethane pro-
duced large nanoparticles with particle size of 210.7 ± 4.8 nm
and 1080 ± 5.4 nm, respectively. This is due to the rapid diffu-
sion of acetone in water than ethanol and dichloromethane.
Similarly, poloxamer 188 gave nanoparticles with narrow size
distribution as compared to SLS and tween 80. Hence, it was
selected for the study, and the results suggest that increas-
ing the surfactant concentration from 0.1% w/v 0.3% w/v, the
f was found decreasing from 129.9 ± 4.2 nm to 92.6 ± 4.6 nm.
Since the poloxamer molecules overlay on the surface of drop-
lets and assist in preventing the coalescence of droplets by
reducing the shear stress during homogenization process. As
a result, the stabilizers which preferentially adsorb at the in-
terface of droplets tend to decrease the particle size of
nanoparticles by merely reducing the tension at interface. From
the results, it was observed that on increasing the polymer con-
centration from 5mg/ml to 20mg/m, the particle size was found
to increase from 104.2 ± 5.7 nm to 151.2 ± 5.1 nm. This effect
can be attributed to the greater number of polymeric chains
per unit volume of solvent which is consequently respon-
sible for the formation of aggregates or larger particles due to
increased polymer–polymer interaction and increased viscos-
ity of organic phase. The amount of acetone as anti-solvent
significantly impacted the particle size of nanoparticles as the
turbidity increased on increasing the volume of anti-solvent
(more than 20 ml) producing larger particles. Among the in-
dependent variables, stirring speed was revealed to have impact
on the particle size of the nanoparticles. High rate of stirring
led to enhanced mass transfer and rate of diffusion between
the multiphase, which induced high homogenization super-
saturation and rapid nucleation to produce smaller sized
nanoparticles. Zeta potential, representing the surface charge,
is indicative of stability of the formulation. Paclitaxel loaded
PLGA nanoparticles exhibited zeta potential in the range of −38
to −42 mV, and this low value of surface charge implicit good
stability by preventing coalescence of particles.
3.2. Entrapment efficiency
The entrapment efficiency of paclitaxel in the PLGA
nanoparticles was found to be influenced by several factors.
Surfactant concentration was found to be crucial in affecting
the entrapment efficiency significantly. As the surfactant con-
centration was increased (from 0.1% w/v to 0.3% w/v), the
entrapment efficiency was found to decrease (from 44.1 ± 6.3%
to 37.6 ± 5.5%), which can be attributed to the diffusion of
paclitaxel from inner core to outer phase of nanoparticles. From
the results, acetone was selected as solvent and poloxamer 188
was selected as stabilizer as they showed good entrapment ef-
ficiency.The rate of addition of anti-solvent (water) was found
insignificant in altering the entrapment efficiency of drug in
polymer when compared to the composition of organic phase
(P > 0.05). Increasing the concentration of acetone has led to
slight increase in entrapment efficiency of paclitaxel from
39.2 ± 5.6% to 42.7 ± 6.4%.The concentration of PLGA was found
to have proportionate direct relationship with entrapment ef-
ficiency of drug. Due to the greater number of polymer chains,
the entrapment efficiency was found to improve.Also, at higher
rates of stirring, the entrapment efficiency increased due to
enhanced the mass transfer and rate of diffusion between the
multiphases. Drying process is found to be insignificant in af-
fecting the entrapment efficiency of drug in NPs (P > 0.05).
3.3. Optimization of nanoparticulate formulation using
23 full factorial design
From the preliminary screening studies Drug: polymer ratio (X1),
poloxamer concentration (X2) and stirring speed (X3) were
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identified as critical process parameters that exhibited con-
siderable effect on the CQAs. Table 1 shows the list of factors
selected for the study along with their levels. In the current
investigation, a design space was obtained for effective de-
signing of formulation that eventually meets the target
specification of the final product by utilizing the novel design
of experiment (DOE) approach. The critical process param-
eters, thus, established were subsequently evaluated for
simultaneous optimization using 23 full factorial design as
shown in Table 2.
From the results, the particle size varied from 92.6 nm to
1080 nm representing substantial dependence of quality at-
tributes on the independent variables. From the polynomial
equation for particle size, it was clear that the independent
Drug: polymer ratio (X1), poloxamer concentration (X2) and stir-
ring speed (X3) have significant impact (P < 0.05) on particle size
and entrapment efficiency of nanoparticles.
From the polynomial equation, it was clear that drug:
PLGA concentration, poloxamer concentration and stirring
speed were inversely proportional to particle size of
nanoparticles. Whereas, drug: PLGA concentration and stir-
ring speed have positive impact on entrapment efficiency.
The relationship between the factors and their coefficients
were determined mathematically with their respective P
values by employing regression analysis, and the factors
obtaining P values < 0.05 were considered as significant. The
results of ANOVA are tabulated in Table 3. From the results of
ANOVA, it was evident that the independent factors possess
significant impact on the particle size as the P values
were well below 0.05. The polynomial equation (equation 7
and 8) is used to obtain useful information in evaluation of
coefficient, while the polynomial model for the estimation of
particle size was as below:
Yparticle size X X X
X X
= − − −
− +
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After the estimation of polynomial equations, the design
space was established by setting the target value for particle
size (<100 nm) and process yield (>40%), and for this design,
response surface plots along with the contour plots were es-
tablished as shown in Fig. 1 which represents the polynomial
equation 7 and equation 8, respectively. The contour plot dis-
plays a nonlinear relationship between the particle size and
the stirring speed, which indicates strong interactions between
these process parameters, especially at high values. Al-
though all contour plots disclosed some degree of interaction,
the effect was more predominant in the drug: polymer ratio
and with stirring speed contour plot.The optimization was per-
formed and the graphs were obtained by using Minitab® 16
statistical software (Minitab Inc, USA).




X1 Drug: polymer ratio 1:02 1:10
X2 Surfactant concentration 0.1% w/v 0.3% w/v
X3 Stirring speed 1000 RPM 2500 RPM
Table 2 – Design layout of 23 full factorial design for optimization of PLGA nanoparticles.
















1 1 1 −1 1:10 0.3% 1000 84.02 31.45
2 1 1 1 1:10 0.3% 2500 76.59 33.61
3 −–1 1 −1 1:02 0.3% 1000 134.39 32.78
4 1 −–1 −1 1:10 0.1% 1000 92.09 42.12
5 −1 −1 −1 1:02 0.1% 1000 141.2 37.32
6 1 −1 1 1:10 0.1% 2500 79.65 44.05
7 −1 1 1 1:02 0.3% 2500 130.62 35.59
8 −1 −1 1 1:02 0.1% 2500 122.24 43.68
Table 3 – Regression coefficients and the respective p values of the independent variables (n = 3).




Coefficient P value Coefficient P value
β0 (constant) 107.66 0.0075 37.575 0.0080
X1 (ratio of Drug: PLGA) −24.512 0.033 0.2325 0.7088
X2 (Concentration of poloxamer 188) −1.195 0.519 −4.2175 0.0710
X3 (stirring speed) −5.325 0.149 1.657 0.176
X1X2 −1.5875 0.4301 −1.06 0.266
X2X3 2.525 0.2971 −0.415 0.5411
X1X3 0.3575 0.8256 −0.635 0.407
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The two dimensional plot obtained by contour plots were
superimposed for simultaneous optimization of the indepen-
dent variables.The desired values for the particle size (<100 nm)
and process yield (>40%) were set to obtain the predicted values
from the set coded values. From the predicted values ob-
tained by overlay of contour plots of both the responses as
depicted in Fig. 2, the actual values were calculated and ex-
perimental trials were performed for ensuring the proper
validation of the process. The observed and predicted values
of optimized nanoparticles formulation were found to be similar
from the checkpoint batches shown in Table 4, thus ensuring
the reliability of the process in obtaining size controlled robust
nanoparticles.
Checkpoint batches were prepared to check the predictive
productivity of the regression equation, and a good correla-
tion was observed between the observed and predicted values.
The optimized formulation obtained exhibited encouraging
results showing particle size of 79.65 ± 3.2 nm as shown in Fig. 3
and % entrapment efficiency of 45.12% ± 2.4% (n = 3), respec-
tively.The scanning electron micrographs (SEM) of glutathione
conjugated paclitaxel loaded PLGA nanoparticles are pre-
sented in Fig. 3.The particles obtained were spherical in shape
with slight aggregation.
Fig. 1 – Two dimensional contour plots for (A) particle size of PLGA nanoparticles, and (B) % entrapment efficiency of PLGA
nanoparticles.
Fig. 2 – Overlay plot for simultaneous optimization of
particle size and % entrapment efficiency of PLGA
nanoparticles.
Table 4 – Checkpoint batches for the validation of regression equation.











Ratio of drug: Polymer 1 76.48 79.97 ± 3.8 45.01 44.29 ± 2.8
Poloxamer 188 concentration −1 77.89 81.09 ± 2.7 44.69 43.77 ± 3.1
Stirring speed 1 76.56 80.24 ± 3.3 44.32 45.03 ± 2.8
n = 3. The data reported were mean values ± SD.
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3.4. Conjugation of glutathione with PLGA nanoparticles
Glutathione, selected as model conjugating agent, was linked
on the surface of the PLGA nanoparticles by using carbodiimide
chemistry. The optimized formulation was subjected to con-
jugation reaction with different concentration of EDAC per
100 mg of nanoparticles. From the results, the concentration
of 150 mg was selected as no significant difference was ob-
served between the two concentrations (P = 0.13).The optimized
formulation exhibited 691.27 ± 151 units of glutathione per
nanoparticle as shown in Table 5.
3.5. In vitro release studies and release kinetics
The release of paclitaxel from the PLGA nanoparticles was de-
termined by using diffusion bag method, and subsequently the
release kinetics profile for the optimized nanoparticle formu-
lation was obtained. Figure 4 clearly shows a biphasic release
pattern of drug from the formulation with an initial burst
release of drug within 2 h followed by sustained release of drug
over a span of 24 h. The initial burst release of drug from
nanoparticles was attributed to the drug molecules present on
the outer surface of the nanoparticles which were dissolved
Fig. 3 – (A) Particle size distribution report and (B) scanning electron micrograph (100 K magnification) of optimized
glutathione conjugated paclitaxel loaded PLGA nanoparticles formulation.
Table 5 – Influence of EDAC concentration on conjugation of glutathione with PLGA nanoparticles.
Amount of EDAC














150 mg 24.66 ± 8.22 691.27 ± 151 130.62 ± 4.8 −39.12 ± 1.6
200 mg 22.24 ± 8.54 678.89 ± 158 136.78 ± 5.2 −38.76 ± 1.4
n = 3. The data reported were mean values ± SD.
Fig. 4 – In vitro release of Paclitaxel from PLGA nanoparticles in phosphate buffer of different pH containing 0.5% SLS. The
data reported were mean values ± SD.
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as soon as they came in contact with the diffusion medium.
The latter sustained release of drug is due to the slow erosion
of the polymer matrix thus releasing the drug in a controlled
manner over 24 h.
3.6. Ex vivo release studies
The ex vivo release of paclitaxel from glutathione conjugated
and unconjugated nanoparticles was performed on excised
nasal mucosa of sheep. The results of ex vivo release studies,
as depicted in Fig. 5, revealed that the release pattern fol-
lowed biphasic pattern as seen in in vitro release studies with
initial burst release of drug followed by slow sustained release
of drug over a period of 48 h. The results concluded that the
glutathione conjugated nanoparticles exhibited better perme-
ability releasing around 75% of drug across mucosal membrane
as compared to unconjugated PLGA nanoparticles (around 25%
drug). In vitro release studies due to the presence of barrier prop-
erties of nasal mucosal membrane. This may be attributed to
the difference in the physicochemical properties of both con-
jugated and unconjugated nanoparticles. Moreover, glutathione
plays an important role in opening of tight junctions of the
mucosal membrane as well as in promoting the paracellular
transport of molecules across mucosal membrane [38]. The ex
vivo drug release profile of the optimized paclitaxel loaded PLGA
nanoparticles was fitted to various kinetic equations and the
parameters like R2, AIC (Akaike information criterion), MSC
(Model selection criteria) were calculated to determine the
release kinetics for paclitaxel loaded PLGA nanoparticles. From
Table 6, it is clear that the release kinetics of glutathione con-
jugated (R2 = 0.9736; AIC = 92.14) and unconjugated PLGA
nanoparticles (R2 = 0.9865; AIC = 50.55) were found to be best
fit for Weibull model among various kinetic models.
3.7. In vivo biodistribution studies
The results of percentage in vivo biodistribution studies are fur-
nished in Fig. 6. From the results, it can be concluded that most
amount of paclitaxel in brain was achieved with glutathione
conjugated nanoparticles (1.72 ± 0.08 μg/g of brain) at the end
of 8 h, when compared to unconjugated paclitaxel loaded PLGA
nanoparticles (0.86 ± 0.01 μg/g of brain) and plain paclitaxel sus-
pension (0.22 ± 0.04 μg/g of brain). From the results, it was clear
that glutathione conjugation aided in enhancing the drug trans-
port to brain across blood–brain barrier by achieving high
concentrations of paclitaxel in brain as compared to plain drug
suspension. Besides, the glutathione conjugated nanoparticles
were taken up and was found to be accumulated in the reticulo
endothelial cells comprising of spleen, kidney and lungs.
The brain targeting efficiency of glutathione conjugated
nanoparticles was found to be 1.72 times greater than the
unconjugated PLGA nanoparticles and 7.8 times as that of plain
paclitaxel suspension, thus demonstrating the potential be-
havior of glutathione in enhancing the drug delivery to brain
by penetrating the blood–brain barrier. The pharmacokinet-
ics, derived from the non-compartmental analysis, are shown
Fig. 5 – Ex vivo release of Paclitaxel from glutathione conjugated and unconjugated PLGA nanoparticles in phosphate buffer
of different pH containing 0.5% SLS. The data reported were mean values ± SD.
Table 6 – Release kinetics of paclitaxel loaded PLGA nanoparticles.
Parameter Weibull Zero order First order Higuchi Korsmeyer–Peppas Hixson-Crowell
R observed 0.9893 0.937807 0.9762 0.9823 0.9824 0.9649
R square 0.9788 0.514734 0.8384 0.9640 0.9640 0.7454
R square adjusted 0.9735 0.514734 0.8384 0.9640 0.9600 0.7454
MSE 10.2904 188.3613 62.7275 13.9635 15.5131 98.8254
MSE_root 3.2079 13.72448 7.9201 3.7368 3.9387 9.9411
Weighting 1 1 1 1 1 1
SS 82.3235 1883.613 627.2754 139.6350 139.6181 988.2540
WSS 82.3235 1883.613 627.2754 139.6350 139.6181 988.2540
AIC 54.5172 84.95042 72.8552 56.3294 58.3280 77.8553
MSC 3.3079 0.54124 1.6408 3.1432 2.9615 1.1862
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in Table 7, and the results revealed that the AUC 0-t of gluta-
thione conjugated PLGA nanoparticles (19.42 ± 0.22%) was
considerably higher than the unconjugated nanoparticles
(9.13 ± 0.41%), thereby showing enhanced bioavailability of
peptide conjugated formulation containing paclitaxel. The
results corroborate the findings that the glutathione conju-
gated PLGA nanoparticles can be effectively used as for brain
delivery of drugs through nasal route.
From the results, it can be concluded that the prepared glu-
tathione conjugated PLGA nanoparticles possessed significant
drug delivery potential (P < 0.05) to the brain as compared to
the plain paclitaxel suspension.
3.8. In vitro-in vivo correlation (IVIVC)
IVIVC was performed to establish the relationship between the
in vitro release and clinical data. Figure 7 shows levy plots ob-
tained from both in vitro release data and ex vivo release data
plotted against in vivo plasma drug concentration-time profile
of glutathione conjugated paclitaxel loaded PLGA nanoparticles.
Both the plots display good correlation between the in vitro and
in vivo data (R2 = 0.9657) as well as ex vivo and in vivo data
(R2 = 0.9714). The data obtained from the in vitro as well as ex
vivo studies was convoluted to achieve the levy plot. More-
over, the percent of drug absorbed (in vivo) was calculated from
Fig. 6 – Bio distribution of (A) plain paclitaxel dispersion (B) paclitaxel loaded PLGA nanoparticles, and (C) glutathione
conjugated paclitaxel loaded PLGA nanoparticles, in various organs at different time intervals. The data reported were
mean values ± SD.
Table 7 – Pharmacokinetic parameters in brain and blood and % brain targeting efficiency of PLGA nanoparticles
following intranasal administration of paclitaxel loaded nanoparticles.
Formulation Tissue AUC0-t (%h) AUC obs0-inf (%h) Cmax % Tmax (h) % Brain targeting
efficiency
Plain drug susp. Blood 67.91 ± 0.44 85.219 ± 0.62 2.05 ± 0.23 8 ± 0.1 –
Brain 3.33 ± 0.30 4.228 ± 0.34 0.14 ± 0.03 2 ± 0.22 –
PLGA NPs Blood 80.31 ± 0.86 94.279 ± 1.08 3.13 ± 0.28 8 ± 0.28 224.327 ± 3.1
Brain 9.13 ± 0.41 11.504 ± 0.48 0.43 ± 0.05 8 ± 0.08
PLGA-Glut-NPs Blood 102.17 ± 0.13 118.219 ± 1.36 3.63 ± 0.26 8 ± 0.11 387.474 ± 9.6
Brain 19.42 ± 0.22 21.566 ± 0.78 0.86 ± 0.06 8 ± 0.24 –
n = 3. The data reported were mean values ± SD.
The following pharmacokinetic parameters were calculated:
AUC = area under curve.
Cmax = Maximum concentration.
Tmax = Time at which Cmax was attained.
t1/2 = Time required by drug for reduction to half of its initial concentration.
MRT = mean residence time.
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Wagner-Nelson method, which was then plotted against the
in vitro release and ex vivo release data (% drug dissolved) to
obtain a plot, the linearity of which signifies the correlation
between the two models. The prediction error was found to
be less than 15%, which indicates good correlation between the
in vivo and in vitro models. Hence, it can be concluded from
the data that the in vitro and ex vivo release data can be used
as a predictive model for in vivo bioavailability of the drug from
PLGA nanoparticles.The levy plots were obtained from R project
software for statistical computing (R-project.org).
The statistical analysis was performed by Tukey’s mul-
tiple comparison test for ensuring the significance of the model
and was evaluated using ANOVA. It was found that the results
of PLGA formulation were found significant (P = −0.4650) when
compared to the plain drug suspension. Further, the results of
ANOVA analysis on brain levels after each formulation dose
suggest that the results for glutathione conjugated PLGA have
come out significantly better (P = −0.245).
4. Conclusion
In the present investigation, an attempt was made to obtain
robust and rugged PLGA based nanoparticulate formulation
loaded with paclitaxel by the aid of statistical DOE design.The
preliminary experiments were conducted to identify the pos-
sible risk associated with the formulation of PLGA nanoparticles.
Later, the impact of each factor on the critical quality attri-
butes of the product was established by utilizing 23 full factorial
design, and design space was constructed using statistical tools.
The results were further fortified by statistical models, contour
plots and response surface plot.Therefore, the objective of ob-
taining paclitaxel loaded PLGA nanoparticles with controlled
size and improved EE can be successfully achieved through
nanoprecipitation technique as well as by novel quality by
design concept. EDAC was used for successful conjugation of
glutathione with PLGA nanoparticles.The in vivo biodistribution
studies revealed excellent transport potential of glutathione
in delivering the drug to the brain in the form of nanoparticles
which was demonstrated to be 7.8 times as that of plain
paclitaxel suspension. Hence, glutathione can be used as an
effective vector in transport of drugs which have limited BBB
permeation.
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